Studie MK7902-015

MK7902-015

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung aktiv

Unbekannt / Unbekannt

Zielgerichtet